Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphomaCustomized targeted therapy in Hodgkin lymphoma: hype or hope?New and emerging HDAC inhibitors for cancer treatmentClassical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysPediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.Panobinostat in lymphoid and myeloid malignancies.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma GroupPhase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine TumorsA Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesGenetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cellsRitonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Challenges and perspective of drug repurposing strategies in early phase clinical trials.Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphomaEpigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.Marine-derived angiogenesis inhibitors for cancer therapy.Relapsed Hodgkin lymphoma: management strategiesBrentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsPhase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
P2860
Q26745842-B5B34113-628B-43B5-9F49-CBD4B415A734Q26749421-AD8C64BF-459D-4F80-9BF0-8061021E328CQ26770716-DBD7411E-5B15-4952-9507-FEF4826605BCQ26771601-588EEF39-812E-40C7-80CB-EF0C32CF099BQ26772848-E01A5581-01AC-4CF7-8B06-46F702B7DF69Q27002554-9DCFAA02-7EDA-47D5-ADCD-5BD9F0EA061BQ27022413-52ACA17B-EDF5-4937-83A0-5802BAF3F002Q27022992-FDFC5A9E-C721-4FF8-8F5A-5F96ECCF5284Q28082536-3E5594FA-F28E-4705-BC45-67483D97908DQ28550025-320770F5-6B40-44EF-A5D2-1D0D44688C67Q30248284-6172ABCE-B895-484F-9BFA-C9A4F7757B70Q33405714-CC1A8818-4570-4B47-B558-D9A27E27CD13Q33405891-4A62A7A3-EF22-4B0C-B088-EF2593246B9AQ33408889-0A21C23E-F988-497B-A917-F4741C27FDB0Q33409579-987C337B-894D-4C52-BCB1-9A9967E6BFEEQ33410761-ED8A40A1-D13E-4C0F-B218-F0208A041B22Q33411127-6ABACF17-5D53-45AC-B358-8F3A54760B14Q33420273-0F3DEF78-DE9F-4F79-B3BC-E8CAE55FBDE5Q33432027-FD6C2953-C480-4659-9FFB-E958B7233045Q33432714-A5BA4DB4-1D0B-4EE8-959E-332369F44C19Q33442755-8C414C61-ED99-4869-92CE-950C1FC541A1Q33704061-D887F0CC-D84D-4BA2-B2BD-B9E1FF4E6C16Q33886267-EE4EF1A8-D24B-4373-A689-CBE1251F115BQ33913937-15F4E10C-D579-4F3E-8769-A895DE2C1581Q33928765-5547E3D5-0E4A-4ABF-BB72-B0B48BD8AE98Q34265747-11704878-3605-4F96-B4F8-63198F34B9FFQ34662648-42E59952-F36E-4C85-9D0F-3025A6098570Q35053177-2D1CECF2-7077-42D1-BEA3-C461C898E3BCQ35214924-EF1D095B-AC80-45C1-AE8D-975A00320519Q35273390-92D4FC33-BF9B-42B7-8C70-FFB5C6592B06Q35561607-C99383E5-96A4-49EE-A19A-CD8F88999982Q35603293-4E3F3F39-5DE2-4386-83E5-AC6AEAC26B5FQ35726371-4BCAE0A8-6AA5-494D-99FB-2FDDD82F1149Q35863063-81BEF80A-713F-4009-B282-82AA09940CFBQ36404763-78B0C7A0-81FF-456D-9CA6-C6C2E8343237Q36738463-B07E0582-B4C0-493F-97BC-E611C2CF6B27Q36994177-4674C536-D349-4C40-800C-5C55882F2FD5Q37008427-E12E7A05-81E6-4B53-9539-CB5766C74EF0Q37060652-C8E068C1-3CF1-4EAB-B0E4-9AE0804682C3Q37150016-98D88AB0-B3C9-43E3-8B5C-4697FD26B0D4
P2860
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Panobinostat in patients with ...... : results of a phase II study.
@ast
Panobinostat in patients with ...... : results of a phase II study.
@en
type
label
Panobinostat in patients with ...... : results of a phase II study.
@ast
Panobinostat in patients with ...... : results of a phase II study.
@en
prefLabel
Panobinostat in patients with ...... : results of a phase II study.
@ast
Panobinostat in patients with ...... : results of a phase II study.
@en
P2093
P356
P1476
Panobinostat in patients with ...... : results of a phase II study.
@en
P2093
Anas Younes
Andreas Engert
Angela Shen
Anna Sureda
Christophe Le Corre
Dina Ben-Yehuda
H Miles Prince
Jennifer Gallagher
Mark Kirschbaum
Patrick Johnston
P304
P356
10.1200/JCO.2011.38.1350
P407
P577
2012-04-30T00:00:00Z